Page 1,251«..1020..1,2501,2511,2521,253..1,2601,270..»

Where Does IFRX Stock Rank in the Biotechnology Industry? – InvestorsObserver

Posted: November 30, 2019 at 4:46 pm

Inflarx NV (IFRX) is near the bottom in its industry group according to InvestorsObserver. IFRX gets an overall rating of 32. That means it scores higher than 32 percent of stocks. Inflarx NV gets a 18 rank in the Biotechnology industry. Biotechnology is number 84 out of 148 industries.

Click Here to get the full Stock Score Report on Inflarx NV (IFRX) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 32 means the stock is more attractive than 32 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Inflarx NV (IFRX) stock is higher by 1.73% while the S&P 500 is down -0.23% as of 11:00 AM on Friday, Nov 29. IFRX has risen $0.06 from the previous closing price of $3.47 on volume of 881,155 shares. Over the past year the S&P 500 has risen 14.93% while IFRX is down -88.36%. IFRX lost -$2.11 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

See the rest here:
Where Does IFRX Stock Rank in the Biotechnology Industry? - InvestorsObserver

Posted in Biotechnology | Comments Off on Where Does IFRX Stock Rank in the Biotechnology Industry? – InvestorsObserver

Strella Biotechnology tackles food waste by ‘hacking the fruit’ – Penn: Office of University Communications

Posted: November 30, 2019 at 4:46 pm

On the second floor of the Pennovation Center, Strella Biotechnology is hard at work turning their student-led startup into a full-fledged company thats ready to make a major impact in the agricultural sector.

May graduates Katherine Sizov and Malika Shukurova, respectively the CEO and head of R&D at Strella, share a 2019 Presidents Innovation Prize, which includes $100,000 of financial support, a $50,000 living stipend for both awardees, and a year of dedicated co-working and lab space at the Pennovation Center. The alumnae and their company are now poised to take on the challenge of $1 trillion worth of food waste.

Strellas biosensors are designed to give packers real-time data on how ripe their fruits are while being stored between harvesting and selling. Using bio-inspired sensors that measure the ethylene gas produced by fruits as they ripen, Strella successfully hacked the fruit to create their patent-pending biosensors. Now, only six months after graduation, Strella has six paying customers and is aiming for $100,000 in sales by the end of the season.

Beyond the work needed to deploy their first paid product, Strella also has a clear view of what needs to be done for future progress of the company. This means running experiments in the lab to refine their current sensors while conducting other experiments that will help the company be able to monitor other types of fresh foods. Its a job that Shukurova says involves a lot of multitasking and requires an all-hands approach to problem solving.

We set up experiments that run for several days, and during that period we work on different tasks. I prepare for the next set of experiments, Jacob [Jordan] and Katherine travel to our customers to deploy sensors, and Zuyang [Liu]]works on IoT [Internet of Things]. At the end of the day we all come together to discuss results and future plans, says Shukurova about their companys work flow.

The company is also finding ways to expand their technology onto individual pallets in retail settings, which represents a huge untapped market for managing food waste. That opportunity, from a numbers perspective, is far greater than the current packing market were working in, so were hoping to make an impact as we move into that space as well, says Sizov.

During the next six months, the team will be busy analyzing the data collected by their deployed sensors and gearing up for a new round of fundraising. Looking further ahead, Strella aims to increase sales in their initial market, conduct research and development on individual pallet-level sensors, and begin active partnerships with larger retailers to help optimize their supply chains.

Sizov admits that Strella has an ambitious timeline but that the team is looking forward to the challenge. Working alongside Jordan, Liu, and Shukurova, Sizov says that Strella already has its own culture of sorts. None of us have ever had a business before, and learning how to create culture within a group, how to work together as a team, and how to not get tired of each other because we spend so much time together, has been an interesting challenge, says Sizov.

Their lab and coworking space at Pennovation has allowed Strella to stay connected with Penns innovator community while also providing lab facilities and resources needed to continue their work on their sensors. Strella has two lab benches and a fume hood, access to shared lab equipment, and plenty of space to house their prototypes, all provided for free as part of their Innovation Prize.

Theyve also been able to stay well-connected to the Penn community as a whole, traveling regularly to campus to meet with faculty, including weekly meetings with their mentorJeffrey Babin. We are not out of [the] Penn mindset, says Shukurova. We dont have to worry about exams, but were still on campus and were still involved with the faculty.

Babin says that Strella is one of the most exciting companies that Ive seen come out of Penn and that the company is in a strong position to make some significant impact on the food supply chain. One of the things thats been strong since the beginning was having an expanded vision: Not just on product development, but getting a customer, he says. They have a really strong sense of whats required to acquire a customer, what the next steps are, and growing both within the initial customer base while expanding to other elements.

When asked what advice they would give to would-be entrepreneurs, Shukurovas advice is to take it as a journey. She encourages students who have an idea to share their thoughts with others to get feedback before beginning any startup endeavor. Talk to more peopledont limit yourself to 10 people, or 20 people, talk to hundreds of people, she says.

Sizov says that the experience of running a startup has been a great learning experience, one that is far less risky than might seem at first, especially thanks to the Innovation Prize. If youre just following your passion, thats not a risk. Youre not putting aside your career, she says. Everything we learn at Strella is directly teaching us how to be better and smarter individuals.

Jeffrey Babin is a practice professor and associate director of the Engineering Entrepreneurship Program in the School of Engineering and Applied Science.

Homepage photo: Presidents Innovation Prize winners Katherine Sizov and Malika Shukurova (front) doing R & D to help design new versions of their fruit-hackingbiosensors at the Pennovation center.

Go here to read the rest:
Strella Biotechnology tackles food waste by 'hacking the fruit' - Penn: Office of University Communications

Posted in Biotechnology | Comments Off on Strella Biotechnology tackles food waste by ‘hacking the fruit’ – Penn: Office of University Communications

ZIOPHARM Oncology, Inc. (ZIOP) vs. Huntsman Corporation (HUN): Breaking Down the Biotechnology Industrys Two Hottest Stocks – E Globalist

Posted: November 30, 2019 at 4:46 pm

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) shares are up more than 181.82% this year and recently decreased -1.50% or -$0.08 to settle at $5.27. Huntsman Corporation (NYSE:HUN), on the other hand, is up 20.27% year to date as of 11/27/2019. It currently trades at $23.20 and has returned 2.11% during the past week.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) and Huntsman Corporation (NYSE:HUN) are the two most active stocks in the Biotechnology industry based on todays trading volumes. Investor interest in the two stocks is clearly very high, but which is the better investment? To answer this question, we will compare the two companies across growth, profitability, risk, and valuation metrics, and also examine their analyst ratings and insider activity trends.

Companies that can increase earnings at a high compound rate over time are attractive to investors. Comparatively, HUN is expected to grow at a 0.70% annual rate. All else equal, HUNs higher growth rate would imply a greater potential for capital appreciation.

Just, if not more, important than the growth rate is the quality of that growth. Growth can actual be harmful to investors if it comes at the cost of weak profitability and low returns. To adjust for differences in capital structure well use EBITDA margin and Return on Investment (ROI) as measures of profitability and return. EBITDA margin of 8.49% for Huntsman Corporation (HUN). ZIOPs ROI is -63.00% while HUN has a ROI of 20.20%. The interpretation is that HUNs business generates a higher return on investment than ZIOPs.

The amount of free cash flow available to investors is ultimately what determines the value of a stock. ZIOPs free cash flow (FCF) per share for the trailing twelve months was -0.06. Comparatively, HUNs free cash flow per share was +1.32. On a percent-of-sales basis, ZIOPs free cash flow was -7.23% while HUN converted 3.23% of its revenues into cash flow. This means that, for a given level of sales, HUN is able to generate more free cash flow for investors.

Liquidity and leverage ratios are important because they reveal the financial health of a company. ZIOP has a current ratio of 10.30 compared to 2.00 for HUN. This means that ZIOP can more easily cover its most immediate liabilities over the next twelve months. ZIOPs debt-to-equity ratio is 0.00 versus a D/E of 0.95 for HUN. HUN is therefore the more solvent of the two companies, and has lower financial risk.

ZIOP trades at a P/B of 8.50, compared to a forward P/E of 11.68, a P/B of 2.15, and a P/S of 0.70 for HUN. Given that earnings are what matter most to investors, analysts tend to place a greater weight on the P/E.

Analyst Price Targets and Opinions

Investors often compare a stocks current price to an analyst price target to get a sense of the potential upside within the next year. ZIOP is currently priced at a -16.35% to its one-year price target of 6.30. Comparatively, HUN is -12.05% relative to its price target of 26.38. This suggests that ZIOP is the better investment over the next year.

Risk and Volatility

To gauge the market risk of a particular stock, investors use beta. Stocks with a beta above 1 are more volatile than the market as a whole. Conversely, a beta below 1 implies below average systematic risk. ZIOP has a beta of 2.53 and HUNs beta is 2.34. HUNs shares are therefore the less volatile of the two stocks.

Analysts often look at short interest, or the percentage of a companys float currently being shorted by investors, to aid in their outlook for a particular stock. ZIOP has a short ratio of 34.54 compared to a short interest of 1.41 for HUN. This implies that the market is currently less bearish on the outlook for HUN.

Huntsman Corporation (NYSE:HUN) beats ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) on a total of 9 of the 14 factors compared between the two stocks. HUN higher liquidity, is more profitable, generates a higher return on investment, has higher cash flow per share and has a higher cash conversion rate. Finally, HUN has better sentiment signals based on short interest.

Here is the original post:
ZIOPHARM Oncology, Inc. (ZIOP) vs. Huntsman Corporation (HUN): Breaking Down the Biotechnology Industrys Two Hottest Stocks - E Globalist

Posted in Biotechnology | Comments Off on ZIOPHARM Oncology, Inc. (ZIOP) vs. Huntsman Corporation (HUN): Breaking Down the Biotechnology Industrys Two Hottest Stocks – E Globalist

Amicus Therapeutics, Inc. (FOLD) vs. Apellis Pharmaceuticals, Inc. (APLS): Comparing the Biotechnology Industrys Most Active Stocks – E Globalist

Posted: November 30, 2019 at 4:46 pm

Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares are up more than 9.97% this year and recently increased 1.49% or $0.15 to settle at $10.53. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), on the other hand, is up 108.79% year to date as of 11/27/2019. It currently trades at $27.54 and has returned -4.04% during the past week.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) and Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) are the two most active stocks in the Biotechnology industry based on todays trading volumes. To determine if one is a better investment than the other, we will compare the two companies growth, profitability, risk, return, and valuation characteristics, as well as their analyst ratings and sentiment signals.

The ability to consistently grow earnings at a high compound rate is a defining characteristic of the best companies for long-term investment. Analysts expect FOLD to grow earnings at a -1.00% annual rate over the next 5 years.

If theres one thing investors care more about than earnings, its cash flow. FOLDs free cash flow (FCF) per share for the trailing twelve months was -0.23. Comparatively, APLSs free cash flow per share was -0.84.

Analysts look at liquidity and leverage ratios to assess how easily a company can cover its liabilities. FOLD has a current ratio of 6.20 compared to 10.10 for APLS. This means that APLS can more easily cover its most immediate liabilities over the next twelve months. FOLDs debt-to-equity ratio is 0.27 versus a D/E of 1.01 for APLS. APLS is therefore the more solvent of the two companies, and has lower financial risk.

FOLD trades at a P/B of 4.90, and a P/S of 17.09, compared to a P/B of 12.58, for APLS. FOLD is the cheaper of the two stocks on book value basis but is expensive in terms of P/E and P/S ratio. Given that earnings are what matter most to investors, analysts tend to place a greater weight on the P/E.

Analyst Price Targets and Opinions

Just because a stock is cheaper doesnt mean theres more value to be had. In order to assess value we need to compare the current price to where its likely to trade in the future. FOLD is currently priced at a -41.11% to its one-year price target of 17.88. Comparatively, APLS is -36.16% relative to its price target of 43.14. This suggests that FOLD is the better investment over the next year.

Insider Activity and Investor Sentiment

Analysts often look at short interest, or the percentage of a companys float currently being shorted by investors, to aid in their outlook for a particular stock. FOLD has a short ratio of 8.66 compared to a short interest of 6.08 for APLS. This implies that the market is currently less bearish on the outlook for APLS.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) beats Amicus Therapeutics, Inc. (NASDAQ:FOLD) on a total of 6 of the 13 factors compared between the two stocks. APLS has higher cash flow per share, generates a higher return on investment and higher liquidity. Finally, APLS has better sentiment signals based on short interest.

See the original post here:
Amicus Therapeutics, Inc. (FOLD) vs. Apellis Pharmaceuticals, Inc. (APLS): Comparing the Biotechnology Industrys Most Active Stocks - E Globalist

Posted in Biotechnology | Comments Off on Amicus Therapeutics, Inc. (FOLD) vs. Apellis Pharmaceuticals, Inc. (APLS): Comparing the Biotechnology Industrys Most Active Stocks – E Globalist

Biotechnology Algae Cultivation Process (Micro Algae) Market Insights, Volume, Opportunities, Type, Product Analysis, and Application (Cellana,…

Posted: November 30, 2019 at 4:46 pm

Global Biotechnology Algae Cultivation Process (Micro Algae) Market Research Reports offer valuable insights and market trends to present the Biotechnology Algae Cultivation Process (Micro Algae) Industry performance. The introduction, product details, Biotechnology Algae Cultivation Process (Micro Algae) marketing strategies, Biotechnology Algae Cultivation Process (Micro Algae) market share, and key players are stated. The industry trends, development plans, prospects, opportunities, and development threats are explained in detail. The CAGR value, technological development, new product launches, and Biotechnology Algae Cultivation Process (Micro Algae) Industry competitive structure is elaborated.

GET A SAMPLE COPY https://reportsvalue.com/report/global-biotechnology-algae-cultivation-process-micro-algae-market-size-status-and-forecast-2019-2025/#Free-Sample-Report

Global Biotechnology Algae Cultivation Process (Micro Algae) Market Analysis By Major Players:

The study report is evaluated on two segments i.e types and applications covering all the analytical data for current and future markets. The geographical regions covered in the report are-

Types of global Biotechnology Algae Cultivation Process (Micro Algae) report-

Applications of global Biotechnology Algae Cultivation Process (Micro Algae) report-

VIEW FULL REPORT DETAILS HERE https://reportsvalue.com/report/global-biotechnology-algae-cultivation-process-micro-algae-market-size-status-and-forecast-2019-2025/

The report discusses gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Biotechnology Algae Cultivation Process (Micro Algae) Market is deeply analyzed based on regions, types, applications, and Companies.

There are 13 chapters to display an in-depth analysis of the report.

Table of contents 1. Report Overview2. Global Growth Trends3. Market Share by Manufacturers4. Market Size by Type5. Market Size by Application6. Production by Regions7. Biotechnology Algae Cultivation Process (Micro Algae) Consumption by Regions8. Company Profiles9. Market Forecast10. Value Chain and Sales Channels Analysis11. Opportunities & Challenges, Threat and Affecting Factors12. Key Findings13. Appendix

ACCESS THE FULL TOC HERE https://reportsvalue.com/report/global-biotechnology-algae-cultivation-process-micro-algae-market-size-status-and-forecast-2019-2025/#Table-Of-Contents

The study objectives are:

About ReportsValue-

Reportsvalue is an involving new idea or methods company in the stream of market research and analytical reporting. By using our services, you will increase the efficiency of your business and enable you to focus on the other vital aspects of your operation, while we look after market research and reporting.

Contact Us-

Mr. Picardo (Sales Manager)Email- inquiry@reportsvalue.comWeb- http://www.reportsvaue.com

Read the original:
Biotechnology Algae Cultivation Process (Micro Algae) Market Insights, Volume, Opportunities, Type, Product Analysis, and Application (Cellana,...

Posted in Biotechnology | Comments Off on Biotechnology Algae Cultivation Process (Micro Algae) Market Insights, Volume, Opportunities, Type, Product Analysis, and Application (Cellana,…

PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019 – Yahoo Finance

Posted: November 30, 2019 at 4:46 pm

PRINCETON, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that Lauren V. Wood, M.D., Chief Medical Officer of PDS Biotechnology, has been selected to deliver an oral presentation on the Companys novel T-cell activating immunotherapy platform, Versamune, at the World Vaccine & Immunotherapy Congress West Coast 2019, taking place on December 2-5, 2019 in San Francisco, CA.

Details for the presentation are below:

Presentation Title: Versamune: A Novel T-cell Activating Immunotherapy PlatformTopic: Engaging T-Cells, Cancer Antibodies, and CombinationsPresenter: Dr. Lauren V. Wood, Chief Medical Officer, PDS BiotechnologyDate: Wednesday, December 4, 2019Time: 3:00pm PST

The Versamune platform is PDS Biotechs proprietary, synthetic lipid-based T-cell activating platform, which works by facilitating several critical immunological pathways. Versamunes mechanism of action involves the effective cross-presentation of tumor antigens via the MHC Class I and Class II pathways to prime tumor-specific CD8+ and CD4+ T-cells as well the potent up-regulation of Type 1 interferon genes within the lymph nodes, promoting effective T-cell migration, activation and proliferation. These mechanisms promote strong in-vivo induction of polyfunctional tumor-targeting CD8+ killer T-cells. Versamunes activation specifically of type 1 interferons coupled with the lack of significant systemic cytokine release results in a highly favorable safety profile that has potential uses in combination with checkpoint inhibitors and other therapeutic agents. In a phase 1 human clinical trial PDS Biotechnologys lead Versamune-based immunotherapy exhibited potent antigen-specific CD8+ T-cell induction with an average of over 20-fold increase in the blood circulation within 14 days of treatment. The strong T-cell induction also resulted in complete regression of lesions in the majority of treated cervical intraepithelial neoplasia (CIN) patients. The ability to induce high levels of CD8+ killer T-cells in vivo has resulted in potent synergy with checkpoint inhibitors in preclinical studies. Upcoming phase 2 clinical trials to confirm the unique synergy will also be presented.

About PDS Biotechnology

PDS Biotechnology is a clinical-stage immuno-oncology company developing multiple therapies based on the Companys proprietary Versamune T-cell activating technology platform. The Versamune platform effectively delivers tumor-specific antigens for in-vivo uptake and processing, while also activating a critical immunological pathway, the type 1 interferon pathway, thus resulting in the production of potent tumor-specific killer T-cells. Using Versamune, PDS Biotechnology is engineering therapies designed to better recognize cancer cells and break down their defense systems to effectively attack and destroy tumors. PDS Biotechnologys pipeline combines the Versamune technology with tumor-specific antigens across several cancer types. To learn more, please visit http://www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0101

PDS Biotechnologys lead candidate, PDS0101, combines the utility of the Versamune platform with targeted antigens in HPV-expressing cancers. In partnership with Merck and the National Cancer Institute (NCI), PDS Biotechnology is advancing PD0101 to Phase 2 studies in head and neck cancer and in HPV-related advanced cancer.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the Company) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Companys management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as may, will, should, would, expect, anticipate, plan, likely,believe,estimate,project,intend,and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability of the Company to integrate Edge and PDS Biotechnology following the merger; the Companys ability to protect its intellectual property rights; competitive responses to the completion of the merger; potential adverse reactions or changes to business relationships resulting from the completion of the merger;the Companys anticipated capital requirements, including the Companys anticipated cash runway and the Companys current expectations regarding its plans for future equity financings; the timing for the Company or its partners to initiate the planned clinical trials for its lead assets, PDS0101 and PDS0102; the Companys interpretation of the results of its Phase 1 trial for PDS0101 and whether such results are sufficient to support additional trials or the future success of such trials;the successful implementation of the Companys research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Companys interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Companys product candidates; the acceptance by the market of the Companys product candidates, if approved;the timing of and the Companys ability to obtain and maintainU.S. Food and Drug Administrationor other regulatory authority approval of, or other action with respect to, the Companys product candidates;and other factors, including legislative, regulatory, political and economic developmentsnot within the Companys control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Companys annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Story continues

More here:
PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019 - Yahoo Finance

Posted in Biotechnology | Comments Off on PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019 – Yahoo Finance

Weekly pick of Neuroscience news from around the world – Brain Tumour Research

Posted: November 30, 2019 at 4:44 pm

This study was reported on at SNO in Phoenix last week and although it is based on a small cohort (number of patients involved) it has generated much excitement because The oncolytic herpes virus type 1 G47 may become a preferred treatment that leads potentially to a cure of malignant glioma in the near future. ( you will need to click through to this page and then click on the first link on that page to access this update)

Some of the biggest names in US paediatric brain tumour research, in collaboration, have discovered that several types of highly aggressive and, ultimately, fatal paediatric brain tumours originate during brain development. The genetic event that triggers the disease happens in the very earliest phases of cellular development, most likely a prenatal stage, and these findings represent a significant advance in understanding these diseases. The research team leader Dr Claudia Kleinman, from the Lady Davis Institute at the Jewish General Hospital in Montreal said The genesis of the tumours means that there are really no environmental instigators or preventive measures that parents can take. Advancing our understanding of these tumours is important because the effects are so devastating, we want to bring hope to the patients."

In other paediatric brain cancer news $150,000 funding has been pledged from the Om Foundation for investigators at Rutgers Cancer Institute of New Jersey to examine a certain type of medication that impacts gene activity in the treatment of Ependymoma , the third most common childhood brain cancer. Treatment results for Ependymoma have been unsatisfactory due to a lack of effective drugs with surgical removal and radiation therapy being the standard treatments, and chemotherapy not being shown to improve survival rates. Sadly, post-intervention recurrence is common.

Ependymomas have many potentially 'good' genes that are silenced through an epigenetic mechanism (epigenetics is the study of inherited changes in gene expression - active versus inactive genes- that do not involve changes to the underlying DNA sequence). This means that these genes are still present in the tumour but not active. Certain medications (epigenetic modifiers) can reactivate these silenced genes causing cancer cells to return to normal and increased cell killing when combined with radiotherapy.

The Om Parikh Memorial Fund for Paediatric Cancer Research was formed to honour Om Parikh, who died of oligodendroglioma last year aged 13.

In industry news, Australian Biotechnology company Kazia Therapeutics saw their share price surge following positive interim results in phase II glioblastoma trial again note small cohort size.

Radiotherapy is essential for treating paediatric brain tumours, but the treatment comes with the risk of cognitive impairment. Researchers in the US and Canada have examined children diagnosed with medulloblastoma and treated them with two different kinds of radiotherapyproton radiotherapy and photon radiotherapyand found those treated with proton radiotherapy had less intellectual decline. One of the issues this raises in the US is that proton radiotherapy is more costly than photon radiotherapy and is not always covered by insurance. The researchers conclude that:If studies continue to demonstrate that proton radiotherapy offers medical and quality of life benefits that are superior to photon radiotherapy, we will need to address barriers to access for paediatric brain tumour patients .

Ending this week with more about Glioblastoma treatments but this time involving drug repurposing; A gene called mucosa-associated lymphoid tissue l (MALT1), is highly active in lymphoma, a type of blood cancer, and blocking MALT1 causes lymphoma cells to die. MALT1 blockers have long been in clinical use for the treatment of blood cancers. European researchers uncovered that targeting MALT1 with MALT1 blockers caused glioblastoma stem cells to undergo a rare form of cellular suicide and that this points to the possibility of further exploring MALT1 inhibitors as potential treatment of glioblastoma.

Related reading:

If you found this story interesting or helpful,sign up to our weekly e-newsand keep up to date with all the latest from Brain Tumour Research.

Read more:
Weekly pick of Neuroscience news from around the world - Brain Tumour Research

Posted in New Jersey Stem Cells | Comments Off on Weekly pick of Neuroscience news from around the world – Brain Tumour Research

Inside the Beltway: Abortion, immigration among forbidden topics at Thanksgiving table – Washington Times

Posted: November 30, 2019 at 4:41 pm

The warnings are already up in the popular press: Conversations during the Thanksgiving feast can be hazardous if they veer into political territory. But political talk can take place in theory: A data research company has now determined what topics are safe to talk about on the holiday.

With some qualitative analysis and a little common sense, weve created a cheat sheet that will help you blaze a path through Thanksgiving dinner that steers clear of treacherous political pitfalls and dangerous inter-uncle conflicts, reports Ranker.com, a Los Angeles-based media company which uses crowdsourcing to rank public opinion on multiple topics, typically at the rate of 15 million votes a month.

They have determined what political topics are the least and the most likely to set off a Thanksgiving dinner squabble. Their judgment is based on 300,000 votes from 40,000 respondents.

The topics to avoid this year: Abortion, immigration, terrorism and gender equality. The topics which are safe for dinnertime discussion: Ineffective government, health care reform and education.

If there are millennials present, they will be triggered, the organization says, by talk of abortion, police brutality and pollution. Generation X members will be set off by such topics as homelessness, affordable housing and campaign finance reform. Baby boomers will go to battle over terrorism, immigration and the moral decline of the nation.

The organization also has warnings for dinner hosts in certain states. If they live in Florida, their guests will be particularly sensitive about discussions of vaccines. In Indiana, its gender equality while Georgia diners are prone to fight over police brutality. Beware of talking about gun control at dinner tables in both California and Missouri; Texans get feisty over moral decline. New Yorkers get upset over transgender issues.

We examined each issue on a case-by-case basis to find the topics that are most likely to cause disagreement, as well as the ones on which people tend to either agree or not care about, Ranker.com explains.

A VERY SPECIALIZED MEAL

While most of us are enjoying turkey and pumpkin pie on Thanksgiving, the staff at one laboratory at Cedars-Sinai Medical Center in Los Angeles will be busy serving a meal to stem cells.

Stem cells do not observe national holidays, says Loren Ornelas-Menendez, manager of the very specialized lab that converts samples of adult skin and blood cells into stem cells which the human body uses to make our cells in the first place.

These special cells help medical scientists learn how diseases develop and how they might be cured. The lab is tending millions of them. Oh, but they have needs.

Stem cells are living creatures that must be hand-fed a special formula each day, monitored for defects and maintained at just the right temperature. And that means the cell lab is staffed every day, 52 weeks a year, the lab notes in a public advisory.

Many people have dogs. We have stem cells, says Ms. Ornelas-Menendez.

Derived from hundreds of healthy donors and patients, the resident induced pluripotent stem cells or iSPCs are keys to potential treatments for diabetes, breast cancer, Alzheimers disease, blindness, Parkinsons disease and Crohns disease, among other conditions. Ten lab technicians monitor the cells through microscopes each day and cull out any cells which have gone awry for one reason or another.

But what do they eat even on Thanksgiving?

While the cells get sorted, a special feeding formula is defrosting in a dozen bottles spread around a lab bench. The formula includes sodium, glucose, vitamins and proteins. Using pipettes, employees squeeze the liquid into food wells inside little compartments that contain the iPSCs. Afterward, they return the cells to their incubators, the lab advises.

Lab director Dhruv Sareen suggests that people consider offering a toast to the stem cells on Thanksgiving.

One day the cells they tend could lead to treatments for diseases that have plagued humankind for centuries, he says. And thats something to be truly thankful for.

THE GIPPERS FAVORITE

Back by popular demand, Inside the Beltway again shares this little known but historic recipe for President Reagans Favorite Macaroni and Cheese enjoyed by Ronald Reagan and his family on Thanksgiving and other holidays. What follows is a step-by-step shared by Mrs. Ronald Reagan, Washington, D.C., Wife of the President in a spiral-bound community cookbook published by the American Cancer Societys Northern Virginia division in 1983. The recipe serves six and is baked at 350 degrees F for 45 minutes.

The directions are from the cookbook reflecting the style, perhaps, of another era:

1/2 pound macaroni, 1 teaspoon butter, 1 egg, beaten; 1 teaspoon salt, 1 teaspoon dry mustard, 3 cups grated cheese, sharp; 1 cup milk.

Boil macaroni in water until tender and drain thoroughly. Stir in butter and egg. Mix mustard and salt with 1 tablespoon hot water and add to milk. Add cheese leaving enough to sprinkle on top. Pour into buttered casserole, add milk, sprinkle with cheese. Bake until custard is set and top is crusty.

Curious about what transpired at a Reagan Thanksgiving? A 1985 Los Angeles Times account noted this:

President and Mrs. Reagan gathered with their family for a quiet Thanksgiving dinner at their fogbound ranch in the Santa Ynez mountains, where the main topic of conversation was the weather. The Reagans did not seem to mind the enforced seclusion as they sat down to a traditional turkey dinner, prepared by Ann Allman, the Reagan familys longtime cook in California. It was an all-American menu that included cornbread dressing, cranberries, string beans, mashed potatoes, salad, pumpkin pie and monkey bread, a family favorite.

POLL DU JOUR

46% of Americans say long standing family tensions are the cause of family fights during holidays.

37% say general politics is the cause; 33% cite the 2020 presidential race.

24% say someones future plans cause the fights; 24% say money.

22% say the behavior of guests; 21% say drinking and alcohol.

18% say holiday cooking is the cause.

Source: A YouGov poll of 1,310 U.S. Adults conducted Sept. 25-26 and released Tuesday.

Have a happy Thanksgiving and thank you for reading Inside the Beltway.

Continue reading here:
Inside the Beltway: Abortion, immigration among forbidden topics at Thanksgiving table - Washington Times

Posted in Missouri Stem Cells | Comments Off on Inside the Beltway: Abortion, immigration among forbidden topics at Thanksgiving table – Washington Times

Intermountain to open new center for pediatric precision medicine – Healthcare IT News

Posted: November 29, 2019 at 11:44 am

Intermountain Primary Children's Hospital, along with University of Utah Health, and Intermountain Precision Genomics are teaming up to launch a pediatric center for personalized medicine that will serve the Intermountain West.

WHY IT MATTERS The center will use precision genomics to discover, address and treat genetic diseases, many of which affect infants and children and can cause life-long disability.

The Center will focus on precision diagnosis, gene therapies and novel therapeutics, and stem cell, immunologic and regenerative medicine.

Precision medicine includes applications across diagnostics, prevention and screening that takes into account individual variabilities in genes, environment, and lifestyle for every individual.

Through its work on precision diagnosis, the Center hopes to provide more targeted care to critically-ill children based on their genetic make-up, where rapid whole genome sequencing can quickly identify genetic causes of hard-to-diagnose diseases.

The initial efforts will be focused on providing answers to critically ill infants in the newborn intensive care unit, and children with severe seizures and heart conditions.

The research into gene therapies and novel therapeutics will help enable children with previously debilitating and fatal genetic diseases, with clinical trials testing gene therapy treatments for Duchenne's Muscular Dystrophy, Adrenoleukodystrophy, and other serious diseases.

The Center is also developing novel therapeutics that target specific diseases and improve health, with a release noting the Center is one of only six hospitals nationwide to provide gene therapy for the common childhood genetic condition spinal muscular atrophy.

Stem cell research uses a child's own cells, or genetically modifies a child's cells and immune system, to fight disease and promote healing, with additional research aimed at developing immunotherapy as a tool to fight pediatric brain tumors.

The organization also noted clinical trials are testing the use of stem cells in repairing diseased hearts and other tissues.

THE LARGER TRENDIntermountain has been busy on this front recently. In June, the health system announced that it is performing a massive clinical DNA study, pairing 500,000 samples drawn from Intermountain Healths patient population and analyzing them with help from deCODE, a subsidiary of Reykjavik-based Amgen.

"Better health and being able to cure common diseases is the promise of precision medicine, but its not happening fast enough," said Dr. Marc Harrison, president and CEO at Intermountain Healthcare, announcing that initiative. "For too long, the genetic code to better health has been locked. This collaboration with deCODE unlocks that insight so we can rapidly advance well-being not only for ourselves and our families, but for generations to come.

Intermountain's new pediatrics personalized medicine announcement also follows Mount Sinai's just-announced plans to build new precision medicine supercomputer, which will have 15 terabytes of memory, 14 petabytes of raw storage and a peak speed of 220 teraflops per second, to manage massive amounts of genomic data.

ON THE RECORD"Our mission is to leverage the expertise of our scientists, the clinical care of our physicians and care-givers, and the dedication of our community, to discover and develop new cures for children," said Dr. Josh Bonkowsky, Intermountain's medical director of the Primary Children's Center for Personalized Medicine, in a statement. "The work we are doing here and now is transforming pediatric medicine. We will not be done until we have put these diseases out of business."

Nathan Eddy is a healthcare and technology freelancer based in Berlin.Email the writer:nathaneddy@gmail.comTwitter:@dropdeaded209

Healthcare IT News is a publication of HIMSS Media.

Go here to read the rest:
Intermountain to open new center for pediatric precision medicine - Healthcare IT News

Posted in Utah Stem Cells | Comments Off on Intermountain to open new center for pediatric precision medicine – Healthcare IT News

Merus N.V. (MRUS) and PolarityTE Inc. (NASDAQ:PTE) Contrasting side by side – The Broch Herald

Posted: November 29, 2019 at 11:44 am

Since Merus N.V. (NASDAQ:MRUS) and PolarityTE Inc. (NASDAQ:PTE) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation of both companies.

Earnings and Valuation

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Merus N.V. and PolarityTE Inc.

Profitability

Table 2 provides Merus N.V. and PolarityTE Inc.s return on equity, net margins and return on assets.

Liquidity

Merus N.V.s Current Ratio and Quick Ratio are 6.4 and 6.4 respectively. The Current Ratio and Quick Ratio of its competitor PolarityTE Inc. are 5.6 and 5.6 respectively. Merus N.V. therefore has a better chance of paying off short and long-term obligations compared to PolarityTE Inc.

Analyst Recommendations

Merus N.V. and PolarityTE Inc. Ratings and Recommendations are available in the next table.

Merus N.V. has a 27.47% upside potential and an average price target of $20. Meanwhile, PolarityTE Inc.s average price target is $9.5, while its potential upside is 197.81%. Based on the analysts opinion we can conclude, PolarityTE Inc. is looking more favorable than Merus N.V.

Institutional & Insider Ownership

Institutional investors held 65.8% of Merus N.V. shares and 45.6% of PolarityTE Inc. shares. 30.47% are Merus N.V.s share held by insiders. Competitively, 33% are PolarityTE Inc.s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Merus N.V. has 12.5% stronger performance while PolarityTE Inc. has -64.71% weaker performance.

Summary

PolarityTE Inc. beats on 6 of the 11 factors Merus N.V.

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies, as well as developing MCLA-158, a bispecific antibody candidate, which is designed to bind to cancer stem cells for the potential treatment of colorectal cancer. Its pre-clinical bispecific antibody candidates include MCLA-134 and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Incyte and ONO Pharmaceutical Co., Ltd. to develop bispecific antibody candidates based on Biclonics technology platform. Merus N.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.

PolarityTE, Inc. operates as a biotechnology and regenerative biomaterials company in the United States. The company focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read more from the original source:
Merus N.V. (MRUS) and PolarityTE Inc. (NASDAQ:PTE) Contrasting side by side - The Broch Herald

Posted in Utah Stem Cells | Comments Off on Merus N.V. (MRUS) and PolarityTE Inc. (NASDAQ:PTE) Contrasting side by side – The Broch Herald

Page 1,251«..1020..1,2501,2511,2521,253..1,2601,270..»